Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau
Jean‐Philippe Courade, Rachel Angers, Georges Mairet‐Coello, et al.
Acta Neuropathologica (2018) Vol. 136, Iss. 5, pp. 729-745
Open Access | Times Cited: 109

Showing 1-25 of 109 citing articles:

Tau molecular diversity contributes to clinical heterogeneity in Alzheimer’s disease
Simon Dujardin, Caitlin Commins, Aurélien Lathuilière, et al.
Nature Medicine (2020) Vol. 26, Iss. 8, pp. 1256-1263
Open Access | Times Cited: 336
A walk through tau therapeutic strategies
Santosh Jadhav, Jesús Ávila, Michael Schöll, et al.
Acta Neuropathologica Communications (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 248
Four-repeat tauopathies
Thomas W. Rösler, Amir Tayaranian Marvian, Matthias Brendel, et al.
Progress in Neurobiology (2019) Vol. 180, pp. 101644-101644
Closed Access | Times Cited: 184
From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy
Morvane Colin, Simon Dujardin, Susanna Schraen‐Maschke, et al.
Acta Neuropathologica (2019) Vol. 139, Iss. 1, pp. 3-25
Open Access | Times Cited: 156
Novel Therapeutic Approaches for Alzheimer’s Disease: An Updated Review
Tien-Wei Yu, Hsien‐Yuan Lane, Chieh‐Hsin Lin
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8208-8208
Open Access | Times Cited: 128
Tau-targeting therapies for Alzheimer disease: current status and future directions
Erin E. Congdon, Changyi Ji, Amber M. Tetlow, et al.
Nature Reviews Neurology (2023) Vol. 19, Iss. 12, pp. 715-736
Closed Access | Times Cited: 122
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease
Edmond Teng, Paul T. Manser, Karen Pickthorn, et al.
JAMA Neurology (2022) Vol. 79, Iss. 8, pp. 758-758
Open Access | Times Cited: 110
Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial
Günter U. Höglinger, Irene Litvan, Nuno Mendonça, et al.
The Lancet Neurology (2021) Vol. 20, Iss. 3, pp. 182-192
Open Access | Times Cited: 106
Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study
Hana Florian, Deli Wang, Steven E. Arnold, et al.
Brain (2023) Vol. 146, Iss. 6, pp. 2275-2284
Open Access | Times Cited: 64
Passive immunotherapy for Alzheimer's disease
Xiaoyi Guo, Yan Li, Denghong Zhang, et al.
Ageing Research Reviews (2024) Vol. 94, pp. 102192-102192
Open Access | Times Cited: 26
Phospho-tau serine-262 and serine-356 as biomarkers of pre-tangle soluble tau assemblies in Alzheimer’s disease
Tohidul Islam, Emily Hill, Eric E. Abrahamson, et al.
Nature Medicine (2025)
Open Access | Times Cited: 5
Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody
Marie Albert, Georges Mairet‐Coello, Clément Danis, et al.
Brain (2019) Vol. 142, Iss. 6, pp. 1736-1750
Open Access | Times Cited: 136
Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial
Adam L. Boxer, Irfan Qureshi, Michael K. Ahlijanian, et al.
The Lancet Neurology (2019) Vol. 18, Iss. 6, pp. 549-558
Closed Access | Times Cited: 125
CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease
Kanta Horie, Nicolas R. Barthélemy, Chihiro Sato, et al.
Brain (2020) Vol. 144, Iss. 2, pp. 515-527
Open Access | Times Cited: 122
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Steven S. Plotkin, Neil R. Cashman
Neurobiology of Disease (2020) Vol. 144, pp. 105010-105010
Open Access | Times Cited: 109
New Insights Into Drug Discovery Targeting Tau Protein
Yoshiyuki Soeda, Akihiko Takashima
Frontiers in Molecular Neuroscience (2020) Vol. 13
Open Access | Times Cited: 106
Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial
Tien Dam, Adam L. Boxer, Lawrence I. Golbe, et al.
Nature Medicine (2021) Vol. 27, Iss. 8, pp. 1451-1457
Closed Access | Times Cited: 102
Current Understanding of Natural Antibodies and Exploring the Possibilities of Modulation Using Veterinary Models. A Review
G. IJsbrand Reyneveld, Huub F. J. Savelkoul, H.K. Parmentier
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 96
Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies
María Stamelou, Gesine Respondek, Nikolaos Giagkou, et al.
Nature Reviews Neurology (2021) Vol. 17, Iss. 10, pp. 601-620
Closed Access | Times Cited: 93
Targeting tau: Clinical trials and novel therapeutic approaches
Lawren VandeVrede, Adam L. Boxer, Manuela Polydoro
Neuroscience Letters (2020) Vol. 731, pp. 134919-134919
Open Access | Times Cited: 81
Current Status of Clinical Trials on Tau Immunotherapies
Changyi Ji, Einar M. Sigurdsson
Drugs (2021) Vol. 81, Iss. 10, pp. 1135-1152
Open Access | Times Cited: 76
Current directions in tau research: Highlights from Tau 2020
Claire E. Sexton, Heather M. Snyder, Dirk Beher, et al.
Alzheimer s & Dementia (2021) Vol. 18, Iss. 5, pp. 988-1007
Open Access | Times Cited: 60
Inhibition of Tau seeding by targeting Tau nucleation core within neurons with a single domain antibody fragment
Clément Danis, Elian Dupré, Orgeta Zejneli, et al.
Molecular Therapy (2022) Vol. 30, Iss. 4, pp. 1484-1499
Open Access | Times Cited: 45
Tau-targeting therapy in Alzheimer’s disease: critical advances and future opportunities
Yi Guo, Song Li, Linghui Zeng, et al.
Ageing and Neurodegenerative Diseases (2022) Vol. 2, Iss. 3, pp. 11-11
Open Access | Times Cited: 41
Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review
J Yang, Weijia Zhi, Lifeng Wang
Molecules (2024) Vol. 29, Iss. 12, pp. 2812-2812
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top